HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.

AbstractPURPOSE:
Chemotherapy-induced alopecia (CIA) is a distressing side effect for women with breast cancer undergoing chemotherapy. Scalp cooling is a method aiming to prevent CIA, but its efficacy is not well defined. Randomized trials until recently and at the time this trial was designed have been lacking.
METHODS:
Patients undergoing (neo)adjuvant chemotherapy for early breast cancer (EBC) were randomized to scalp cooling (CAP) or observation (NoCAP). All patients received 18-24 weeks of anthracycline- and/or taxane-based chemotherapy. The primary endpoint was patient-reported rate of alopecia according to a modified version of the Dean Scale. Hair preservation was defined as hair loss ≤ grade 2 (≤ 50%). Secondary endpoints were rate of alopecia determined by medical staff, rate of wig/scarf use, tolerability as well as quality of life (QoL).
RESULTS:
Seventy-nine patients were randomized. Hair preservation was observed in 39.3% of patients in the CAP arm versus 0% in the NoCAP arm (p < 0.001). Wig/scarf use was significantly less frequent in the CAP group (40.7% vs 95.5% outside home before cycle 3, p < 0.001). The drop-out rate was 31.7% and 34.2% in the CAP and NoCAP arm, respectively. Main reasons for drop-out were hair loss, adverse events (CAP), and randomization into control arm. We observed no differences in efficacy between anthracycline-based and non-anthracycline-based regimens. QoL did not differ between the study arms.
CONCLUSIONS:
This trial adds to the evidence that scalp cooling effectively prevents CIA in a meaningful number of patients. This option should be made available for patients undergoing (neo)adjuvant chemotherapy for EBC.
AuthorsKatharina Smetanay, Philippe Junio, Manuel Feißt, Julia Seitz, Jessica Cecile Hassel, Luisa Mayer, Lina Maria Matthies, Arina Schumann, André Hennigs, Jörg Heil, Christof Sohn, Dirk Jaeger, Andreas Schneeweiss, Frederik Marmé
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 173 Issue 1 Pg. 135-143 (Jan 2019) ISSN: 1573-7217 [Electronic] Netherlands
PMID30255454 (Publication Type: Journal Article, Randomized Controlled Trial)
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Alopecia (chemically induced, prevention & control)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Female
  • Hair
  • Humans
  • Hypothermia, Induced (methods)
  • Middle Aged
  • Neoadjuvant Therapy (adverse effects, methods)
  • Prospective Studies
  • Quality of Life
  • Scalp

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: